Trends in vascular risk factors and medication use in patients with various manifestations of vascular diseases or type 2 diabetes mellitus from 1996 to 2007: The Second Manifestations of ARTerial disease study

European Journal of Preventive Cardiology

Volumn 17, Issue 6, 2010, Pages 628-636

  Vlek, Anne ^a   Visseren, Frank ^a   Algra, Ale ^a,b   Soedamah Muthu, Sabita ^a   Moll, Frans ^a   Doevendans, Pieter ^a   Kappelle, Jaap ^a   Van Der Graaf, Yolanda ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

diabetes mellitus; risk factors; trends; vascular disease

Indexed keywords

ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE;

AGED; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG UTILIZATION; FEMALE; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; NETHERLANDS; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 79851514025     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e328336a0f8     Document Type: Article

References (29)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 1997; 349: 1498–1504.
2. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction. in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952.
3. Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc Dis 2002; 13 (Suppl 1):1–6.
4. The DECODE study group. European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617–621.
5. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24: 1601–1610.
6. Menotti A, Lanti M, Kromhout D, Blackburn H, Nissinen A, Dontas A, et al. Forty-year coronary mortality trends and changes in major risk factors in the first 10 years of follow-up in the seven countries study. Eur J Epidemiol 2007; 22: 747–754.
7. Kotseva K, Stagmo M, De Bacquer D, De Backer G, Wood D. Treatment potential for cholesterol management in patients with coronary heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis 2008; 197: 710–717.
8. Pyorala K, Lehto S, De BD, De SJ, Sans S, Keil U, et al. Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys. Diabetologia 2004; 47: 1257–1265.
9. Boersma E, Keil U, De Bacquer D, De Backer G, Pyorala K, Poldermans D, et al. Blood pressure is insufficiently controlled in European patients with established coronary heart disease. J Hypertens 2003; 21: 1831–1840.
10. Scholte Op, Reimer W, de Swart E, De Bacquer D, Pyorala K, Keil U, Heidrich J, et al. Smoking behaviour in European patients with established coronary heart disease. Eur Heart J 2006; 27: 35–41.
11. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008; 263: 336–352.
12. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol 1999; 15: 773–781.
13. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375–2414.
14. Pyorala K, De BG, Graham I, Poole-Wilson P, Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300–1331.
15. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998; 19 (Suppl A):A12–A19.
16. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, et al. Triglycerides and the risk of coronary heart disease: 10 158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation 2007; 115: 450–458.
17. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357: 1301–1310.
18. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001; 357: 995–1001.
19. Reiner Z, Mihatov S, Milicic D, Bergovec M, Planinc D. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study). Eur J Cardiovasc Prev Rehabil 2006; 13: 646–654.
20. Jankowski P, Kawecka-Jaszcz K, Bilo G, Pajak A. Determinants of poor hypertension management in patients with ischaemic heart disease. Blood Press 2005; 14: 284–292.
21. Antikainen RL, Moltchanov VA, Chukwuma C Jr, Kuulasmaa KA, Marques-Vidal PM, Sans S, et al. Trends in the prevalence, awareness, treatment and control of hypertension: the WHO MONICA Project. Eur J Cardiovasc Prev Rehabil 2006; 13: 13–29.
22. Amar J, Chamontin B, Genes N, Cantet C, Salvador M, Cambou JP. Why is hypertension so frequently uncontrolled in secondary prevention? J Hypertens 2003; 21: 1199–1205.
23. Bleich S, Cutler D, Murray C, Adams A. Why is the developed world obese? Annu Rev Public Health 2008; 29: 273–295.
24. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, Fortmann S, Sans S, Tolonen H, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHO MONICA Project populations. Lancet 2000; 355: 675–687.
25. Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, between 1982 and 1993. Circulation 2000; 102: 1511–1516.
26. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–2572.
27. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462–1536.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
29. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.